You are here

Article Text

Article menu
Download PDFPDF
Poster and E-Posters
13. Vaginal and vulvar cancer
145 Survival in lymph node positive vulvar cancer patients treated with adjuvant radiotherapy versus chemoradiotherapy
  1. Beatriz Navarro Santana1,
  2. Octavio Arencibia Sanchez1,
  3. Maria Laseca-Modrego2,
  4. Daniel Gonzalez Garcia-Cano1,
  5. Andrés Rave-Ramírez2,
  6. Avinash Ramchandani Vaswani1 and
  7. Alicia Martín Martínez3
  1. 1Complejo Hospitalario Universitario Insular Materno Infantil de Canarias, Las Palmas De Gran Canaria, Spain
  2. 2Maternal and Child University Hospital of Canary Islands, Las Palmas De Gran Canaria, Spain
  3. 3Hospital Materno Infantil de Las Palmas, Las Palmas, Spain

Abstract

Introduction/Background Vulvar cancer is uncommon accounting for 6330 new cases and 1560 deaths in USA in 2022

ESGO guidelines concluded that, sentinel node macrometastasis (>2 mm) are to be treated with inguinal lymphadenectomy followed by radiotherapy in cases with more than one metastatic lymph node and/or extracapsular spread with a II level of evidence and grade A of recommendation- Also, the ESGO guidelines states that adjuvant chemoradiotherapy should be considered with a IV level of evidence and grade B of recommendation.

Methodology Retrospective cohort study which evaluated patients diagnosed with squamous vulvar cancer and positive inguinal lymph nodes. These patients were treated with radiotherapy or with concurrent chemoradiotherapy (cisplatin 40mg/m2 per week) after vulvectomy and inguinal lymphadenectomy. The study took place in Hospital Materno Infantil de Las Palmas, Spain from 1990 to 2022

Results A total of 27 patients were included, 17 in the group of radiotherapy only and 10 in the group of chemoradiotherapy. There were not differences in terms of age (P=0.27), ECOG status (P=0.091), FIGO 2021 stage(P=0.921), in tumor grade (P=0.449), lymphovascular invasion (P=0.315), the tumor size (P=0.165), the number of lymph node yielded (P=0.56), the number of positive lymph nodes (P=0.147), the surgical margins (P=0.328). In the radiotherapy group there were more radical vulvectomies than in the chemoradiotherapy group (P=0.001).

There were not significant differences in overall survival between the radiotherapy alone group vs the chemoradiotherapy group (Log-rank test, P=0.24). In multivariate analysis, only age was a significant prognostic factor for overall survival (HR:1.17, CI95%: 1.05–1.31, P=0.006), however chemoradiotherapy was not significant in univariate (HR:0.52, CI 95%:0.17–1.62, P=0.23) and multivariate analysis (HR:0.09, CI 95%:0.01–1.09, P=0.058).

Conclusion In our study chemoradiotherapy was not an independent prognostic factor for overall survival. We should be cautious interpreting those results because of the small sample of this study and its retrospective nature.

Disclosures No disclosures.

https://doi.org/10.1136/ijgc-2024-ESGO.1034

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.